First Trust Advisors LP Takes Position in OPKO Health, Inc. $OPK

First Trust Advisors LP acquired a new position in shares of OPKO Health, Inc. (NASDAQ:OPK) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 500,273 shares of the biotechnology company’s stock, valued at approximately $570,000. First Trust Advisors LP owned about 0.07% of OPKO Health as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Zacks Investment Management bought a new position in shares of OPKO Health during the fourth quarter valued at $27,000. StoneX Group Inc. acquired a new position in OPKO Health during the 4th quarter worth about $27,000. Apella Capital LLC acquired a new position in OPKO Health during the 1st quarter worth about $34,000. Cibc World Markets Corp bought a new stake in shares of OPKO Health in the 4th quarter valued at about $34,000. Finally, EP Wealth Advisors LLC bought a new stake in shares of OPKO Health in the 4th quarter valued at about $37,000. 64.63% of the stock is currently owned by institutional investors.

OPKO Health Stock Performance

Shares of OPK stock opened at $1.39 on Wednesday. The firm has a market capitalization of $1.04 billion, a PE ratio of -15.44 and a beta of 1.51. The firm has a fifty day simple moving average of $1.38 and a two-hundred day simple moving average of $1.27. The company has a current ratio of 3.35, a quick ratio of 2.93 and a debt-to-equity ratio of 0.28. OPKO Health, Inc. has a 12 month low of $0.98 and a 12 month high of $1.73.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings data on Monday, July 27th. The biotechnology company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.07. The firm had revenue of $163.58 million for the quarter, compared to analyst estimates of $131.23 million. OPKO Health had a negative net margin of 12.40% and a negative return on equity of 5.88%. The business’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period last year, the firm earned ($0.19) earnings per share. Analysts forecast that OPKO Health, Inc. will post -0.24 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Barrington Research cut OPKO Health from an “outperform” rating to a “market perform” rating in a report on Wednesday, April 29th. Weiss Ratings upgraded OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, May 18th. HC Wainwright reissued a “buy” rating on shares of OPKO Health in a research report on Wednesday, July 29th. Finally, Wall Street Zen raised OPKO Health from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, OPKO Health has an average rating of “Hold” and a consensus price target of $1.55.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.